

**U.S. FDA APPROVES ADDITIONAL INDICATION FOR
EISAI'S ANTICANCER AGENT LENVIMA[®] IN COMBINATION WITH EVEROLIMUS
AS TREATMENT FOR**

[Notes to editors]

1. About Lenvima (lenvatinib mesylate)

Lenvima is an orally administered multiple receptor tyrosine kinase (RTK) inhibitor with a novel binding mode that selectively inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors (VEGFR1, VEGFR2